Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-Exposure Prophylaxis (PrEP) of COVID-19
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that Pemgarda™ (pemivibart), formerly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Princeton, N.J. and Tokyo, Japan– March 21, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
BASKING RIDGE, N.J., March 21, 2024. Lisata Therapeutics, Inc. (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
SOUTH SAN FRANCISCO, Calif.,– March 21, 2024– Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis
BOSTON, March 21, 2024. Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Inflammation-Reducing Drug Minocycline Shows No Benefit For Dry Age-Related Macular Degeneration in NIH Trial
March 20, 2024 -- The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Experimental Gene Therapy for Giant Axonal Neuropathy Shows Promise in NIH Clinical Trial
March 20, 2024 -- An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
CAMBRIDGE, Mass., March 19, 2024. The Bill& Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuation
JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Model
March 18, 2024 -- Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), successfully alleviated pain and inflammation in a rodent model of endometriosis, according to researchers funded by the National Institutes of Health (NIH). They chose the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials
NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front.
myTomorrows is a global health technology company shaping the future landscape of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 15, 2024 Category: Pharmaceuticals Source Type: clinical trials
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
